RMC-5845 / Revolution Medicines - LARVOL DELTA

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress (GlobeNewswire) - "The company expects to submit an investigational new drug application (IND) for RMC-6291 in the first half of 2022....The company expects to submit an IND for RMC-6236 in the first half of 2022....RMC-4630 monotherapy has shown initial clinical anti-tumor activity in multiple cancer genotypes....The company expects to disclose a safety data set from the dose escalation portion of this trial in the first half of 2021....The company intends to evaluate RMC-5845 for treatment of certain genetically defined RAS-dependent cancers. Recently advanced into IND-enabling development. The company expects to submit an IND in the second half of 2021."

IND • P1 data • Oncology • Solid Tumor

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) - “As a centerpiece of the update, Dr. Goldsmith will announce the entry of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development and will discuss the profiles of these development candidates and next steps for advancing them. Dr. Goldsmith will also provide an update on the company’s three RAS Companion Inhibitors, including RMC-4630 (SHP2 inhibitor), RMC-5552 (mTORC1-selective inhibitor), and a new member, RMC-5845 (SOS1-selective inhibitor).”

Pipeline update • Oncology